ABBV/Roche—FDA approves Venclexta (venetoclax) for second-line CLL with 17p deltion: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm495253.htm The approval came three months before the (7/11/16) PDUFA date.